Working… Menu

A Safety and Feasibility Study of Mitotane in Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02057237
Recruitment Status : Completed
First Posted : February 7, 2014
Results First Posted : December 17, 2015
Last Update Posted : December 17, 2015
Information provided by (Responsible Party):
University Health Network, Toronto

Brief Summary:
  1. The primary objective of this study is to assess the feasibility of treating patients with metastatic castration resistant prostate cancer with mitotane. Secondary objectives are to assess safety and tolerability as well as response rate of therapy
  2. To assess the toxicity of Mitotane in men with HRPC
  3. To assess the relationship between baseline serum adrenal androgens and their response to Mitotane

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: Mitotane Phase 1

Detailed Description:

All patients will undergo pre-study assessment for symptoms, performance status, ECG, CT abdomen/pelvis, Bone scan, Complete blood count tests(hematology) , Biochemistry tests like serum electrolytes, liver function tests, coagulation profile, testosterone and PSA tests.

Mitotane will be administered 1.5g daily escalation to maximum of 5 g daily then adjusted according to serum levels and tolerability

Physical examinations, hematology, biochemistry tests, and toxicity evaluations will be measured throughout patients on protocol treatment

Mitotane serum level will be analyzed every second cycle

Research bloods include; ACTH, cortisol, deoxycorticosterone, aldosterone, corticosterone, and testosterone, androstenedione, dehydroepiandrostenedione (DHEA), DHEA sulfate (DHEA-S) and estradiol will be collected only in cycle 1,3 and 5

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Safety and Feasibility Study of Mitotane in Prostate Cancer
Study Start Date : September 2013
Actual Primary Completion Date : April 2015
Actual Study Completion Date : October 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer
Drug Information available for: Mitotane

Arm Intervention/treatment
Experimental: single arm
Mitotane will be administered on an outpatient or inpatient basis.
Drug: Mitotane
Mitotane will be administered at a starting dose of 1.5 g/day and increased in case of good gastrointestinal tolerance every 3rd day by 0.5 g up to a maximal dose of 5.0 g and then adjusted according to blood concentrations monthly and tolerability, up to a maximum of 10g daily
Other Name: Lysodren

Primary Outcome Measures :
  1. The Primary Endpoint is the Proportion of Patients Maintained on Mitotane After 12 Consecutive Weeks of Therapy. A Positive Outcome Would be Seeing 50% or More Patients Maintained on Therapy. Secondary Endpoint Include Proportion of Adverse Events [ Time Frame: maintain 50% of the patients on Mitotane at the 12 week mark ]

Secondary Outcome Measures :
  1. Prostate Specific Antigen (PSA) Response Rate [ Time Frame: PSA progression free survival and excessive toxicity. Plan to keep the patients on Mitotane for atleast 8 weeks, despite increasing level of PSA as other trials shown early increase in PSA followed by a subsequent decline. ]

    Continue increase of serum PSA beyond 8 weeks indicate PSA progression. Response and progression will be primarily evaluated in this study using PSA response criteria from the Prostate Cancer Working Group 2. Criteria used to define response include: at least a 50% decline in PSA, confirmed by a second measurement ≥4 weeks later. PSA progression is defined by a >25% increase from baseline in patients whose PSA did not decrease, and of 50% from the nadir value in patients whose PSA decreased. This increase in PSA must be >5 ng/ml, and confirmed by a second measurement, at least 1 week later; PSA nadir is defined as the minimum PSA value that was confirmed by a second measurement.

    PSA progression free survival is defined as the time between the randomization date and the date of PSA progression or the date of death due to prostate cancer, whichever occurs first.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Biopsy-proven prostate cancer OR a clinical picture consistent with metastatic prostate cancer with high levels of serum PSA (>20ng/ml)
  • Progressed on docetaxel chemotherapy after a minimum of 3 cycles and/or stopped treatment because of toxicity. Patients may have had previous mitoxantrone, either before or after docetaxel treatment
  • Response to a minimum of a 50% fall in PSA maintained for 4 weeks and then progressed through abiraterone treatment
  • At least 2 consecutive rising PSAs measured at least 1 week apart . Patients must have ceased abiraterone at least 1 week prior.
  • Serum PSA > 10 ng/ml
  • ECOG performance status </= 1 (Karnofsky >/=60%)
  • Normal organ and marrow function as defined:

    • Absolute neutrophils count ≥ 1,500/uL
    • platelets ≥100,000/uL
    • total bilirubin ≤1.5 X institutional ULN
    • AST(SGOT)/ALT(SGPT) ≤ 2 X institutional ULN
    • creatinine ≤ 1.5 X institutional ULN
  • Men must agree to use adequate contraception prior to study entry
  • Life expectancy > 3 months
  • CRPC documented by PSA increase despite having: a) orchidectomy OR b) continuous LHRH agonist treatment. This should be documented by a baseline serum testosterone suppression (<1.75 nmol/L)

Exclusion Criteria:

  • Prior anticancer treatment with Mitotane
  • May not be receiving any other investigational or anticancer agents while on study
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure or evidence of cardiac dysfunction, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease, poorly controlled diabetes mellitus, clinically significant or untreated ophthalmologic (e.g. Sjogrens etc.) or gastrointestinal conditions (e.g. Crohns disease, ulcerative colitis) or psychiatric illness/social situations that would limit compliance with study requirements
  • Active malignancy at any other site excluding squamous cell or basal cell carcinomas of the skin
  • Radiotherapy within the past 4 weeks
  • Pre-existing pituitary or adrenal dysfunction
  • Patients on spironolactone as this may interfere with the action of mitotane
  • Patients on warfarin as mitotane may unpredictably interfere with INR measurements

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02057237

Layout table for location information
Canada, Ontario
University Health Network
Toronto, Ontario, Canada, M5G 2M9
Sponsors and Collaborators
University Health Network, Toronto
Layout table for additonal information
Responsible Party: University Health Network, Toronto Identifier: NCT02057237    
Other Study ID Numbers: MITO222
First Posted: February 7, 2014    Key Record Dates
Results First Posted: December 17, 2015
Last Update Posted: December 17, 2015
Last Verified: November 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Prostatic Diseases
Antineoplastic Agents, Hormonal
Antineoplastic Agents